Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study
Geeta Gulati, MD; Siri L. Heck, MD; Helge Røsjø, MD, PhD; Anne H. Ree, MD, PhD; Pavel Hoffmann, MD, PhD; Tor-Arne Hagve, MD, PhD; Jon Norseth, MD; Berit Gravdehaug, MD; Kjetil Steine, MD, PhD; J€urgen Geisler, MD, PhD; Torbjørn Omland, MD, PhD, MPH
J Am Heart Assoc. 2017 Nov 8;6(11). pii: e006513. doi: 10.1161/JAHA.117.006513
CARDIONCOLOGY.ORG ABSTRACT:
The aim of this study was to assess: (1) longitudinal change in circulating cardiovascular biomarkers, (2) the effect of metoprolol succinate and candesartan cilexetil on the biomarker response, and (3) the associations between on-treatment changes in biomarker concentrations and subsequent left ventricular dysfunction in patients with early breast cancer receiving anthracyclines.
Results indicate that treatment with anthracycline in early breast cancer is associated with an increase in circulating cardiovascular biomarkers. This increase is, however, not associated with early decline in ventricular function.
© All Rights Reserved